COCKS, BENJAMIN,TESTER, ANGUS,HOBMAN, PETER,MCDONAGH, MATTHEW
申请号：
NZ58930609
公开号：
NZ589306A
申请日:
2009.05.14
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Provided is the use of angiogeninn the manufacture of a medicament for promoting development of a hemovascular network particularly following heart attack, promoting wound healing, providing a neuroprotective effect, treating neurodegenerative diseases, treating ALS, treating motor neuron disease, inhibiting replication of RNA viruses in primary activated T cells and chronically infected cells, treating RNA infection by Retroviridae, Cystoviridae, Birnaviridae, Reoviridae, Coronaviridae, Flaviviridae, Togaviridae, "Arterivirus", Astroviridae, Caliciviridae, Picornaviridae, Potyviridae, Orthomyxoviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, and Bunyaviridae, treating human immunodeficiency virus, increasing bone density, treating disorders of bone homeostasis, treating osteoporosis, especially in the elderly and/or postmenopausal women, treating glucocorticoid- induced osteoporosis, treating osteopenia, treating osteoarthritis, treating osteoporosis-related fractures, and treating low bone mass due to chronic glucocorticoid therapy, wherein the medicament is for administering orally and the angiogenin is provided in the absence of a carrier, excipient or encapsulation means intended to facilitate delivery of angiogenin to the bloodstream without substantial degradation in the gut.
